Sonnet BioTherapeutics (SONN) Competitors $6.37 -1.21 (-15.96%) As of 02:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. IVVD, THTX, ACOG, MOLN, PLX, CHRS, BHST, ELDN, ACTU, and CTORShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Invivyd (IVVD), Theratechnologies (THTX), Alpha Cognition (ACOG), Molecular Partners (MOLN), Protalix BioTherapeutics (PLX), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Eledon Pharmaceuticals (ELDN), Actuate Therapeutics (ACTU), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors Invivyd Theratechnologies Alpha Cognition Molecular Partners Protalix BioTherapeutics Coherus Oncology BioHarvest Sciences Eledon Pharmaceuticals Actuate Therapeutics Citius Oncology Sonnet BioTherapeutics (NASDAQ:SONN) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Do analysts rate SONN or IVVD? Sonnet BioTherapeutics presently has a consensus price target of $20.00, indicating a potential upside of 214.71%. Invivyd has a consensus price target of $3.18, indicating a potential upside of 166.39%. Given Sonnet BioTherapeutics' higher possible upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Invivyd.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has stronger earnings & valuation, SONN or IVVD? Sonnet BioTherapeutics has higher earnings, but lower revenue than Invivyd. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$1M43.39-$7.44MN/AN/AInvivyd$25.38M5.66-$169.93M-$0.92-1.30 Does the media prefer SONN or IVVD? In the previous week, Invivyd had 2 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 3 mentions for Invivyd and 1 mentions for Sonnet BioTherapeutics. Invivyd's average media sentiment score of 0.65 beat Sonnet BioTherapeutics' score of 0.00 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in SONN or IVVD? 9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 8.5% of Sonnet BioTherapeutics shares are owned by insiders. Comparatively, 25.4% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, SONN or IVVD? Sonnet BioTherapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Is SONN or IVVD more profitable? Sonnet BioTherapeutics has a net margin of 0.00% compared to Invivyd's net margin of -238.33%. Invivyd's return on equity of -177.89% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -4,646.10% -342.21% Invivyd -238.33%-177.89%-90.96% SummaryInvivyd beats Sonnet BioTherapeutics on 10 of the 15 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.19M$3.13B$5.77B$10.40BDividend YieldN/A2.37%5.74%4.64%P/E RatioN/A20.9177.0926.80Price / Sales43.39387.70494.34162.00Price / CashN/A45.3237.1760.63Price / Book-8.959.7213.816.41Net Income-$7.44M-$53.02M$3.29B$271.62M7 Day Performance7.71%1.42%1.20%2.96%1 Month Performance99.22%8.17%6.49%9.80%1 Year Performance-23.62%10.44%81.94%31.48% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.0079 of 5 stars$6.37-16.0%$20.00+214.0%-5.3%$43.49M$1M0.0010News CoverageGap DownIVVDInvivyd3.4959 of 5 stars$1.29+0.4%$3.18+147.7%+6.8%$154.38M$25.38M-1.40100THTXTheratechnologiesN/A$3.32+0.8%N/A+175.8%$152.42M$84.38M-17.45140Short Interest ↓ACOGAlpha Cognition1.9008 of 5 stars$9.42-0.3%$20.00+112.3%N/A$152.23MN/A-5.89N/AMOLNMolecular Partners1.7429 of 5 stars$3.75+0.8%$8.00+113.3%-23.7%$151.43M$5.65M-1.80180News CoveragePLXProtalix BioTherapeutics1.9642 of 5 stars$1.90-0.8%$15.00+691.6%+70.6%$149.50M$61.95M-14.42200CHRSCoherus Oncology4.2125 of 5 stars$1.30+2.0%$4.51+248.5%+45.7%$149.47M$266.96M0.83330Gap UpBHSTBioHarvest SciencesN/A$9.08+3.1%$13.67+50.5%N/A$149.09M$25.19M-12.97N/AGap UpHigh Trading VolumeELDNEledon Pharmaceuticals2.9735 of 5 stars$2.42-1.5%$10.00+312.9%+2.0%$145.51MN/A-2.0810Positive NewsShort Interest ↓Gap UpACTUActuate Therapeutics2.0663 of 5 stars$6.94-0.9%$20.33+193.0%-14.3%$145.35MN/A0.0010CTORCitius Oncology1.8672 of 5 stars$1.89+2.7%$3.00+58.7%+10.8%$144.20MN/A0.00N/APositive News Related Companies and Tools Related Companies Invivyd Competitors Theratechnologies Competitors Alpha Cognition Competitors Molecular Partners Competitors Protalix BioTherapeutics Competitors Coherus Oncology Competitors BioHarvest Sciences Competitors Eledon Pharmaceuticals Competitors Actuate Therapeutics Competitors Citius Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts